Eighteen insiders at Attovia Therapeutics, Inc. (ATTO) have recently made significant purchases of the company's stock, collectively acquiring approximately $92.56 million worth of shares. Transactions occurred on August 13, 2026, with shares bought at both $17.00 and $21.00.
Among the notable buyers were entities associated with Goldman Sachs, including Sachs & Co. LLC, Sachs Group Inc, and Sachs Asset Management, L.P., each acquiring substantial blocks of shares. Broad Street Principal Investments, L.L.C., West Street Life Sciences I, L.P., and WSLS entities also participated in the buying activity. Colin Walsh, a Director at Attovia Therapeutics, was also among the insiders making purchases.
This cluster of insider buying, where multiple individuals or entities within a company buy shares around the same time, is often interpreted as a strong bullish signal by market observers, suggesting confidence in the company's future prospects.